about
A phase 2 study of vorinostat in acute myeloid leukemiaNeoadjuvant therapy for gastric cancer: current evidence and future directionsKDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal CancerNovel approaches for myelodysplastic syndromes: beyond hypomethylating agents.Persistent Tn polyagglutination syndrome during febrile neutropenia: a case report and review of the literatureA retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.Clinical utility of aromatase inhibitors as adjuvant treatment in postmenopausal early breast cancer.Pelvic angiosarcoma occurring in a postmenopausal female: case report and review of the literature.Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer.Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution.Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system.Primary care challenges and the educational pipeline in the 21st centuryFull dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinomaSDHB mutation carriers with malignant pheochromocytoma respond better to CVDNext-generation sequencing and personalized genomic medicine in hepatobiliary malignanciesImmune checkpoint inhibitors for hepatocellular carcinoma
P50
Q24643266-D6D3CBCE-A11A-4265-8E00-7A85E51922F9Q26781043-ECCA7D39-EEE5-4099-9ABB-3D05BB3C896BQ27853363-4DE2C846-66BF-4DC3-9BA2-3FBC526F1C5EQ33388356-560629BC-F63C-414B-A5EC-1D5B1512A1C7Q33393659-19C3F6AB-588C-4220-BCD4-8EBFB451CB80Q33401476-24338BA7-1C78-43AC-9C84-8F21EF065333Q33807542-CB1B6755-FACD-4DDB-910B-3007AC7FB8BAQ34550326-788009D6-94CD-4EFD-84B7-8A796EF0640AQ37615072-EF87874E-791A-4011-8DB7-F48FF1301708Q38028410-D79DF21B-F1C8-4345-BEDA-D2281E04B2F8Q38139996-7D952654-7BDC-4633-B3C5-1AE3B1528570Q39754979-889FCFAB-6ECD-42E2-A5AE-3FD31D573D6EQ45221360-84C1F8ED-46D5-45EC-AE62-75C4FB43680BQ83129827-83CB5D7A-033A-42BA-B124-0CBF85FF235DQ86290561-AF297FEA-90B2-4C0D-B1D1-B090A18F8039Q88203219-8EC1CB45-DFDA-472D-B42D-6C1CB6477D34Q91323814-9C44C94D-6E5E-41B1-B0D5-2097A63813A9Q91323869-A35EC08C-A71B-45A4-9ED3-8A5EDACC4B5F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Arturo Loaiza-Bonilla
@ast
Arturo Loaiza-Bonilla
@en
Arturo Loaiza-Bonilla
@es
Arturo Loaiza-Bonilla
@nl
type
label
Arturo Loaiza-Bonilla
@ast
Arturo Loaiza-Bonilla
@en
Arturo Loaiza-Bonilla
@es
Arturo Loaiza-Bonilla
@nl
prefLabel
Arturo Loaiza-Bonilla
@ast
Arturo Loaiza-Bonilla
@en
Arturo Loaiza-Bonilla
@es
Arturo Loaiza-Bonilla
@nl
P106
P1153
35076923900
P21
P31
P496
0000-0002-3655-9602